Thomas N Chase

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Striatal glutamatergic mechanisms and extrapyramidal movement disorders
    Thomas N Chase
    National Institutes of Health, Experimental Therapeutics Branch, NINDS, NIH, Building 10, Room 5C103, Bethesda, MD, USA
    Neurotox Res 5:139-46. 2003
  2. ncbi request reprint Glutamate release inhibition ineffective in levodopa-induced motor complications
    William Bara-Jimenez
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Mov Disord 21:1380-3. 2006
  3. ncbi request reprint Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates
    Francesco Bibbiani
    Experimental Therapeutic Branch, Building 10, Room 5C103, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892 1406, USA
    Exp Neurol 192:73-8. 2005
  4. ncbi request reprint Dopamine modulates the response of the human amygdala: a study in Parkinson's disease
    Alessandro Tessitore
    Clinical Brain Disorders Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1384, USA
    J Neurosci 22:9099-103. 2002
  5. ncbi request reprint Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
    William Bara-Jimenez
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Mov Disord 20:932-6. 2005
  6. ncbi request reprint Complications of a trophic xenotransplant approach in parkinsonian monkeys
    Pierre J Blanchet
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Prog Neuropsychopharmacol Biol Psychiatry 27:607-12. 2003
  7. ncbi request reprint Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease
    William Bara-Jimenez
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mov Disord 19:1183-6. 2004
  8. ncbi request reprint Striatal plasticity and extrapyramidal motor dysfunction
    Thomas N Chase
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Building 10, Room 5C103, 90900 Rockville Pike, Bethesda, MD 20892, USA
    Parkinsonism Relat Disord 10:305-13. 2004
  9. ncbi request reprint Renaissance of amantadine in the treatment of Parkinson's disease
    Pierre J Blanchet
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Adv Neurol 91:251-7. 2003
  10. ncbi request reprint Mapping of rat brain using the Synuclein-1 monoclonal antibody reveals somatodendritic expression of alpha-synuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies
    Gerda Andringa
    Experimental Therapeutics Branch, NINDS, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Neuropathol Exp Neurol 62:1060-75. 2003

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Striatal glutamatergic mechanisms and extrapyramidal movement disorders
    Thomas N Chase
    National Institutes of Health, Experimental Therapeutics Branch, NINDS, NIH, Building 10, Room 5C103, Bethesda, MD, USA
    Neurotox Res 5:139-46. 2003
    ..These observations lend new insight into molecular mechanisms contributing to the integration of synaptic inputs to spiny neurons. They also suggest novel approaches to the pharmacotherapy of extrapyramidal motor dysfunction...
  2. ncbi request reprint Glutamate release inhibition ineffective in levodopa-induced motor complications
    William Bara-Jimenez
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Mov Disord 21:1380-3. 2006
    ..Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD...
  3. ncbi request reprint Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates
    Francesco Bibbiani
    Experimental Therapeutic Branch, Building 10, Room 5C103, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892 1406, USA
    Exp Neurol 192:73-8. 2005
    ..However, these primates remained 'ON' for only 90 min and within 7-10 days all developed severe dyskinesias. Implanted monkeys evidenced local irritation, which was alleviated by steroid co-therapy...
  4. ncbi request reprint Dopamine modulates the response of the human amygdala: a study in Parkinson's disease
    Alessandro Tessitore
    Clinical Brain Disorders Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1384, USA
    J Neurosci 22:9099-103. 2002
    ..Furthermore, consistent with findings in experimental animal paradigms, our results provide in vivo evidence of the role of dopamine in modulating the response of the amygdala to sensory information in human subjects...
  5. ncbi request reprint Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
    William Bara-Jimenez
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Mov Disord 20:932-6. 2005
    ....
  6. ncbi request reprint Complications of a trophic xenotransplant approach in parkinsonian monkeys
    Pierre J Blanchet
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Prog Neuropsychopharmacol Biol Psychiatry 27:607-12. 2003
    ..Membrane biophysics, the cell type used, and the extended period of time the devices remained in situ may have contributed to the negative outcome and should be addressed in future investigations using this approach...
  7. ncbi request reprint Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease
    William Bara-Jimenez
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mov Disord 19:1183-6. 2004
    ..The drug was well tolerated. Under the conditions of this study, the present results failed to support the usefulness of dopamine reuptake inhibition in the treatment of advanced Parkinson's disease...
  8. ncbi request reprint Striatal plasticity and extrapyramidal motor dysfunction
    Thomas N Chase
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Building 10, Room 5C103, 90900 Rockville Pike, Bethesda, MD 20892, USA
    Parkinsonism Relat Disord 10:305-13. 2004
    ..These findings have already yielded new insight into mechanisms subserving motor memory and synaptic integration as well as accelerated development of novel approaches to the improved treatment of motor disability...
  9. ncbi request reprint Renaissance of amantadine in the treatment of Parkinson's disease
    Pierre J Blanchet
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Adv Neurol 91:251-7. 2003
  10. ncbi request reprint Mapping of rat brain using the Synuclein-1 monoclonal antibody reveals somatodendritic expression of alpha-synuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies
    Gerda Andringa
    Experimental Therapeutics Branch, NINDS, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Neuropathol Exp Neurol 62:1060-75. 2003
    ..We explore possible explanations for the differences in conflicting reports of patterns of alpha-synuclein expression in brain, including differences among antibodies...
  11. ncbi request reprint Dopaminergic modulation of cortical function in patients with Parkinson's disease
    Venkata S Mattay
    Clinical Brain Disorders Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20982 1379, USA
    Ann Neurol 51:156-64. 2002
    ....
  12. ncbi request reprint Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells
    Xiaoxia Wang
    National Institute of Neurological Disorders and Stroke, Experimental Therapeutics Branch, Bethesda, Maryland, USA
    J Neurochem 83:1094-102. 2002
    ..PGA1 appears to protect against rotenone-induced cell death by inducing HSPs and blocking nuclear translocation of NF-kappaB in a process that attenuates caspase-3 activation, but is not mediated by its inhibition...
  13. pmc Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats
    Justin D Oh
    Department of Psychology, Sloan 224, Central Michigan University, Mount Pleasant, MI 48859, USA
    Brain Res 971:18-30. 2003
    ....
  14. ncbi request reprint Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models
    Justin D Oh
    Department of Psychology, Central Michigan University, Sloan 224, Mount Pleasant, Michigan 48859, USA
    Exp Neurol 177:557-64. 2002
    ..Moreover, our findings may indicate that 5HT2A/C receptor-mediated mechanisms, alone or in combination with other mechanisms, contribute to the pathogenesis of the altered motor responses associated with the treatment of PD...
  15. ncbi request reprint Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats
    Justin D Oh
    Department of Psychology, Central Michigan University, Mt Pleasant, Michigan, USA
    J Neurosci Res 72:768-80. 2003
    ....
  16. ncbi request reprint Neuroprotective effects of prostaglandin A1 in animal models of focal ischemia
    Hui Ling Zhang
    Department of Pharmacology, Soochow University School of Medicine, 48 Ren Ming Road, Suzhou 215007, PR China
    Brain Res 1039:203-6. 2005
    ..01) when administered immediately following permanent ischemia in rats. PGA1 treatment also significantly ameliorated motor dysfunction after brain ischemia. These results suggest that PGA1 protects neurons from ischemic injury...
  17. ncbi request reprint Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity
    Zhong qin Liang
    Department of Pharmacology, Soochow University School of Medicine, Suzhou 215007, P R China
    Neurobiol Dis 20:562-73. 2005
    ..The selective vulnerability of striatal medium spiny neurons to degeneration in a rodent model of Huntington's disease appears to correlate with their low levels of Bcl-2-i and high levels of induced p53-i and c-Myc-i...
  18. ncbi request reprint NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53
    Zhong qin Liang
    Department of Pharmacology, Soochow University School of Medicine, Suzhou Singapore Industrial Park, Suzhou 215123, China
    Brain Res 1145:190-203. 2007
    ..These results suggest that NF-kappaB activation contributes, at least in part, to oxidative stress-induced degeneration of dopaminergic neurons through a NF-kappaB-dependent p53-signaling pathway...
  19. ncbi request reprint Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum
    Zhong qin Liang
    Department of Pharmacology, Soochow University School of Medicine, Suzhou, China
    J Neurosci Res 85:1295-309. 2007
    ..Excitotoxin-induced neuronal apoptosis may thus result from, at least partially, a failed cell cycle attempt...